Does SodaMelt Have Side Effects?

Yes, and the ones worth knowing about come from a single family of ingredients rather than from the capsule as a whole.

Four of the eleven blend entries are anthraquinone botanicals: Chinese rhubarb root, aloe vera leaf, cascara sagrada bark and buckthorn bark. That class has a well-known and well-documented effect profile, and it is the reason this page runs long.

A fifth entry, goldenseal root, is the interaction rather than the side effect. Two more, psyllium and bentonite, have handling considerations rather than adverse effects. Everything else on the panel is uneventful.

The left-hand column collects what buyers describe to the distributor. The middle column attributes it to the panel entry whose known mechanism fits.

Four of the eleven entries in this blend belong to one chemical family, and what that family does is the largest single thing to understand about the capsule. It gets a section here rather than a footnote.

Anthraquinone glycosides pass the small intestine intact, are cleaved by colonic bacteria, and the freed compound stimulates the colonic wall. Motility rises, water reabsorption falls, and a bowel movement follows six to twelve hours later. That is a stimulant laxative mechanism and it is the same one a pharmacy senna tablet uses.

van Gorkom's review of anthranoid laxatives is the standard reference on where the class stands. Its conclusion is about duration: long-term use cannot be recommended. Nascimbeni's risk assessment is the study most often cited alongside it, measuring anthranoid laxative use at 32.7 per cent among patients with sigmoid cancer against 8.3 per cent among controls. That is an observational association in a case-control design, which is a reason for caution about duration rather than a demonstration that the laxatives caused the cancers.

The visible consequence of long use has its own name, melanosis coli, a brown discoloration of the colonic lining that shows up at colonoscopy and reverses after the laxative stops. It is not itself harmful. It is evidence of how long someone has been taking something.

Aloe and cascara sagrada are not arbitrary examples of the class. They are the two ingredients named in a specific federal action, and the detail is worth having exactly right.

The final rule, 67 FR 31125, was published on 9 May 2002 and took effect on 5 November 2002. The agency had moved aloe and cascara sagrada into category III and asked for mutagenicity, genotoxicity and carcinogenicity data. The data did not arrive. The rule concludes that both are not generally recognised as safe and effective, or are misbranded, as over-the-counter drug ingredients.

Here is what that does and does not mean. It governs over-the-counter DRUGS. A dietary supplement is regulated under a different statute, and that is the route this capsule takes, so the rule does not prohibit either ingredient here. What it does establish is that a regulator looked at these two specific plants, asked for safety data, and did not get it.

Both readings are true at once. Treating the rule as a ban on this product would be wrong; treating it as irrelevant would be worse. It is a piece of regulatory history attached to two of the eleven names on this panel, and a buyer is entitled to know it is there.

Cascara sagrada is the entry with case reports attached, and the honest way to present a case report is as a case report.

Nadir's published case describes intrahepatic cholestasis with portal hypertension in a patient who had taken a cascara product, and the paper reviews herbal hepatotoxicity around it. The LiverTox entry for cascara keeps the record current and is the place to read the whole file rather than a single case.

Aloe has its own toxicity literature. Guo and Mei's review collects the adverse clinical effects reported for aloe vera preparations, and the NCCIH page is the plain-language version of the same material.

What a case report establishes is that something happened once and was written down. It does not establish a rate, and nobody should read one as a probability. What it does do is tell you which organ to think about, and for cascara the answer is the liver. Yellowing of the skin or eyes, dark urine, or pain under the right ribs are reasons to stop and be seen, whatever the cause turns out to be.

The lactation records sit alongside these. LactMed for aloe, for rhubarb and for buckthorn all advise against use while breastfeeding, and all three give the same reason: the cathartic activity of the anthraquinones.

Goldenseal is a different kind of risk from the four stimulant entries. It is not something you feel. It is something that changes what another tablet does.

Gurley's in vivo probe study gave healthy volunteers goldenseal and measured cytochrome P450 activity directly. CYP3A4 and CYP2D6 both fell substantially, while other botanicals tested alongside did not move them. A second clinical assessment confirmed the CYP2D6 result. The digoxin study used 3,210 mg a day of standardised extract, which is the figure that makes the exposure concrete.

Those two enzymes between them handle a very large share of oral medicines: many statins, several blood pressure drugs, a number of antidepressants, some anticoagulants and a long list besides. Inhibiting them means a medicine is cleared more slowly, so its level rises without anyone changing the prescription.

The critical review of goldenseal and its constituents collects the efficacy and toxicology literature, and the NCCIH page states the interaction concern in one paragraph. LactMed covers breastfeeding separately.

A short list, and none of it is ambiguous.

• Cramping or urgency that is unpleasant rather than merely noticeable. The anthraquinone class is dose-related, and the answer is to stop rather than to persevere.
• Yellowing of the skin or eyes, dark urine, or pain under the right ribs. Stop and be seen the same week. The cascara literature is the reason this is on the list.
• Blood in the stool, or black tarry stools. That needs an examination regardless of what you have been taking.
• A reaction that looks allergic: rash, swelling, wheeze, tightness. Psyllium has a published anaphylaxis case behind it.
• A prescription medicine behaving differently, whether stronger or weaker. That is the goldenseal conversation, and it happens before the next capsule.
• Diarrhoea lasting more than a couple of days. Fluid and electrolyte loss is the real risk of a stimulant laxative used too long, and it does not need to be dramatic to matter.

Two of those are reasons to see a doctor rather than to consult a page, and this site would rather be clear about that than hedge it. The refund desk on +1 (302) 200-3480 does not need a reason, and the refund policy covers an opened bottle.